107 related articles for article (PubMed ID: 26975214)
21. A computational study to identify the key residues of peroxisome proliferator-activated receptor gamma in the interactions with its antagonists.
Sharifi T; Ghayeb Y
J Biomol Struct Dyn; 2018 May; 36(7):1822-1833. PubMed ID: 28566016
[TBL] [Abstract][Full Text] [Related]
22. Structural design and synthesis of arylalkynyl amide-type peroxisome proliferator-activated receptor γ (PPARγ)-selective antagonists based on the helix12-folding inhibition hypothesis.
Ohashi M; Gamo K; Tanaka Y; Waki M; Beniyama Y; Matsuno K; Wada J; Tenta M; Eguchi J; Makishima M; Matsuura N; Oyama T; Miyachi H
Eur J Med Chem; 2015 Jan; 90():53-67. PubMed ID: 25461311
[TBL] [Abstract][Full Text] [Related]
23. Structural Biology Inspired Development of a Series of Human Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) Ligands: From Agonist to Antagonist.
Miyachi H
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835351
[TBL] [Abstract][Full Text] [Related]
24. Multi-conformation dynamic pharmacophore modeling of the peroxisome proliferator-activated receptor γ for the discovery of novel agonists.
Sohn YS; Park C; Lee Y; Kim S; Thangapandian S; Kim Y; Kim HH; Suh JK; Lee KW
J Mol Graph Model; 2013 Nov; 46():1-9. PubMed ID: 24104184
[TBL] [Abstract][Full Text] [Related]
25. PPARγ Corepression Involves Alternate Ligand Conformation and Inflation of H12 Ensembles.
Frkic RL; Pederick JL; Horsfall AJ; Jovcevski B; Crame EE; Kowalczyk W; Pukala TL; Chang MR; Zheng J; Blayo AL; Abell AD; Kamenecka TM; Harbort JS; Harmer JR; Griffin PR; Bruning JB
ACS Chem Biol; 2023 May; 18(5):1115-1123. PubMed ID: 37146157
[TBL] [Abstract][Full Text] [Related]
26. Exploring Flexibility of Progesterone Receptor Ligand Binding Domain Using Molecular Dynamics.
Zheng L; Lin VC; Mu Y
PLoS One; 2016; 11(11):e0165824. PubMed ID: 27824891
[TBL] [Abstract][Full Text] [Related]
27. Different structures of the two peroxisome proliferator-activated receptor gamma (PPARγ) ligand-binding domains in homodimeric complex with partial agonist, but not full agonist.
Ohashi M; Oyama T; Miyachi H
Bioorg Med Chem Lett; 2015 Jul; 25(13):2639-44. PubMed ID: 25987371
[TBL] [Abstract][Full Text] [Related]
28. Structural basis for telmisartan-mediated partial activation of PPAR gamma.
Amano Y; Yamaguchi T; Ohno K; Niimi T; Orita M; Sakashita H; Takeuchi M
Hypertens Res; 2012 Jul; 35(7):715-9. PubMed ID: 22357520
[TBL] [Abstract][Full Text] [Related]
29. Structural Basis for the Regulation of PPARγ Activity by Imatinib.
Jang JY; Kim HJ; Han BW
Molecules; 2019 Oct; 24(19):. PubMed ID: 31581474
[TBL] [Abstract][Full Text] [Related]
30. The nuclear receptor PPARγ individually responds to serotonin- and fatty acid-metabolites.
Waku T; Shiraki T; Oyama T; Maebara K; Nakamori R; Morikawa K
EMBO J; 2010 Oct; 29(19):3395-407. PubMed ID: 20717101
[TBL] [Abstract][Full Text] [Related]
31. Structural insight into peroxisome proliferator-activated receptor gamma binding of two ureidofibrate-like enantiomers by molecular dynamics, cofactor interaction analysis, and site-directed mutagenesis.
Pochetti G; Mitro N; Lavecchia A; Gilardi F; Besker N; Scotti E; Aschi M; Re N; Fracchiolla G; Laghezza A; Tortorella P; Montanari R; Novellino E; Mazza F; Crestani M; Loiodice F
J Med Chem; 2010 Jun; 53(11):4354-66. PubMed ID: 20462215
[TBL] [Abstract][Full Text] [Related]
32. [Design and Synthesis of Peroxisome Proliferator-activated Receptor (PPAR) Gamma Antagonists Based on the Principle of Operation of Nuclear Receptor I].
Ohashi M; Miyachi H
Yakugaku Zasshi; 2017; 137(8):957-967. PubMed ID: 28768949
[TBL] [Abstract][Full Text] [Related]
33. Partial agonists activate PPARgamma using a helix 12 independent mechanism.
Bruning JB; Chalmers MJ; Prasad S; Busby SA; Kamenecka TM; He Y; Nettles KW; Griffin PR
Structure; 2007 Oct; 15(10):1258-71. PubMed ID: 17937915
[TBL] [Abstract][Full Text] [Related]
34. Structural Studies on the Binding Mode of Bisphenols to PPARγ.
Useini A; Schwerin IK; Künze G; Sträter N
Biomolecules; 2024 May; 14(6):. PubMed ID: 38927044
[TBL] [Abstract][Full Text] [Related]
35. Helix 12 dynamics and thyroid hormone receptor activity: experimental and molecular dynamics studies of Ile280 mutants.
Souza PC; Barra GB; Velasco LF; Ribeiro IC; Simeoni LA; Togashi M; Webb P; Neves FA; Skaf MS; Martínez L; Polikarpov I
J Mol Biol; 2011 Oct; 412(5):882-93. PubMed ID: 21530542
[TBL] [Abstract][Full Text] [Related]
36. Protein polarization is critical to stabilizing AF-2 and helix-2' domains in ligand binding to PPAR-gamma.
Ji CG; Zhang JZ
J Am Chem Soc; 2008 Dec; 130(50):17129-33. PubMed ID: 19007119
[TBL] [Abstract][Full Text] [Related]
37. Structural review of PPARγ in complex with ligands: Cartesian- and dihedral angle principal component analyses of X-ray crystallographic data.
Kaupang Å; Laitinen T; Poso A; Hansen TV
Proteins; 2017 Sep; 85(9):1684-1698. PubMed ID: 28543443
[TBL] [Abstract][Full Text] [Related]
38. Conformational dynamics of the estrogen receptor alpha: molecular dynamics simulations of the influence of binding site structure on protein dynamics.
Celik L; Lund JD; Schiøtt B
Biochemistry; 2007 Feb; 46(7):1743-58. PubMed ID: 17249692
[TBL] [Abstract][Full Text] [Related]
39. A widely used retinoic acid receptor antagonist induces peroxisome proliferator-activated receptor-gamma activity.
Schupp M; Curtin JC; Kim RJ; Billin AN; Lazar MA
Mol Pharmacol; 2007 May; 71(5):1251-7. PubMed ID: 17290005
[TBL] [Abstract][Full Text] [Related]
40. Peroxisome proliferator-activated receptor gamma (PPARγ) has multiple binding points that accommodate ligands in various conformations: Structurally similar PPARγ partial agonists bind to PPARγ LBD in different conformations.
Ohashi M; Gamo K; Oyama T; Miyachi H
Bioorg Med Chem Lett; 2015 Jul; 25(14):2758-62. PubMed ID: 26025876
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
